J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.

Color of cells,Particles in liquid

On an earnings call dominated by discussion about the impact of biosimilar competition to its top-seller Remicade (infliximab), Johnson & Johnson pointed to a growing oncology business and an abundant late-stage pipeline on Oct. 18, saying it will file 10 new molecular entities for approval during 2015-2019 that have blockbuster sales potential.

In cancer, Worldwide Chairman-Pharmaceuticals Joaquin Duato cited continued sales growth for Imbruvica (ibrutinib) and a promising launch for Darzalex (daratumumab)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.